Navigation Links
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
Date:11/19/2009

Nutra Pharma has introduced Nyloxin OTC, an over-the-counter pain reliever, that will be marketed and sold through international distribution channels alongside the Company's prescription pain reliever, Nyloxin Rx.

Plantation, FL (Vocus) November 19, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today the introduction of Nyloxin OTC for the treatment of chronic pain. Nyloxin OTC will be marketed and sold internationally alongside the Company's prescription pain reliever, Nyloxin Rx.

"Nyloxin OTC is an important addition to our line of pain relievers and offers many benefits similar to that of Cobroxin, our over-the-counter pain reliever currently being marketed and sold in the United States" explained Dr. Paul Reid, CEO of ReceptoPharm. "By introducing our pain relievers internationally under a single, unified brand, Nyloxin, we can better leverage our growth overseas as we complete the required registrations and build awareness for both our prescription pain reliever, Nyloxin Rx, as well as our over-the-counter pain reliever, Nyloxin OTC," he added.

Nutra Pharma recently announced its intention to begin the drug registration process for its pain relievers in Canada, Europe, and South America. The Company expects to have these registrations completed in the near term and plans to subsequently launch Nyloxin Rx and Nyloxin OTC in those territories through select international licensees.

"The international pain market represents a significant growth opportunity for our company, especially in countries where there is limited access to opiate-based medicines," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. "With the introduction of Nyloxin OTC, we now believe we can offer a more well-rounded product line that covers a much broader spectrum of the pain management market," he concluded.

Nyloxin OTC, which was developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com
http://www.ReceptoPharm.com
http://www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Introducing Nyloxin OTC for international distribution should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

# # #

Read the full story at http://www.prweb.com/releases/Nutra_Pharma/Nyloxin_OTC/prweb3231994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
2. Vivakor Presents at Nutraceutical Event
3. Reportlinker Adds US World Nutraceutical Ingredients Industry
4. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
5. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
6. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
7. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
8. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
9. HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals
10. Nutrition 21 Launches New Innovative PRESCRIPTIX(TM) Nutraceuticals Product Line
11. Synutra Annual Report on Form 10-K Includes Going Concern Explanatory Paragraph from Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. ... before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New ... help hundreds of uninsured and underinsured people receive much-needed dental care. , This ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces the ... print component of “Revolutionizing Cancer Care” is distributed within the February 12 issue ... with a circulation of approximately 250,000 copies and an estimated readership of 750,000 ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Drug Categories: Strategies for Health Plans and PBMs,” an upcoming Feb. 24 webinar ... affordability and access in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 (Kanadische ... http://www.sedar.com ) und der Website ... --> http://www.sedar.com ) und ... abrufbar.    --> Telesta ... Konzernabschluss des zweiten Quartals und die ...
(Date:2/12/2016)... 2016  Sequent Medical, Inc. gab heute bekannt, ... eine Studie zur Sicherheit und Wirksamkeit des WEB™-Systems ... Behandlung von rupturierten intrakraniellen Aneurysmen begonnen hat. Prof. ... an der Universitätsklinik Bicètre in Paris ... den ersten Patienten aufgenommen. Im Rahmen ...
(Date:2/12/2016)... AUSTIN, Texas , Feb. 12, 2016 ... Institute for Robotic Surgery at St. David,s North Austin ... the da Vinci ® Xi ® Surgical ... ® 7000dV. Thiru Lakshman , M.D., ... performed a total proctocolectomy utilizing Integrated Table Motion technology, ...
Breaking Medicine Technology: